135MO Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
| Autor: | Ajani, J.A., Lordick, F., Bang, Y-J., Enzinger, P.C., Ilson, D.H., Shah, M.A., van Cutsem, E., Xu, R-H., Aprile, G., Xu, J., Pazo Cid, R.A., Kang, Y-K., Yang, J., Moran, D., Bhattacharya, P., Matsangou, M., Arozullah, A., Park, J.W., Shitara, K. |
|---|---|
| Zdroj: | In Annals of Oncology November 2023 34 Supplement 4:S1524-S1525 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|